Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 | MicrobiomeTrials← Back to trialsNCT06714006
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-04-07Est. Completion: 2028-11
Enrollment target: 166 participants Locations- South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,, Southport, Gold Coast, Australia
- Concord Repatriation General Hospital, Concord, New South Wales, Australia
- Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive, Liverpool, New South Wales, Australia
- Scientia Clinical Research, Randwick, New South Wales, Australia
- Sydney Adventist Hospital, Wahroonga, New South Wales, Australia
- Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road, Westmead, New South Wales, Australia
- Mater Hospital Brisbane, South Brisbane, Queensland, Australia
- St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
- Sunshine Hospital, Western Centre for Health Research and Education, Level 3, 176-190 Furlong Road, Saint Albans, Victoria, Australia
- Linear Clinical Research, Joondalup, Western Australia, Australia
- Prince of Wales Hospital, Shatin, New Territories, Hong Kong
- Pacific Clinical Research Network Auckland, Takapuna, Auckland, New Zealand
Other microbiome trials you might be interested in
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by th…
Baltimore, United StatesEst. completion Sep 30, 2029
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene varian…
Alabaster, United StatesEst. completion Dec 31, 2026